Kahn Brothers Group Inc. Has $2.13 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Kahn Brothers Group Inc. increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 15.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,591 shares of the medical equipment provider’s stock after buying an additional 4,000 shares during the quarter. Hologic comprises about 0.5% of Kahn Brothers Group Inc.’s portfolio, making the stock its 16th biggest position. Kahn Brothers Group Inc.’s holdings in Hologic were worth $2,134,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HOLX. Barclays PLC grew its position in Hologic by 47.6% in the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after purchasing an additional 231,578 shares in the last quarter. Franklin Resources Inc. boosted its position in Hologic by 171.7% in the third quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider’s stock worth $22,714,000 after purchasing an additional 175,855 shares during the last quarter. Principal Financial Group Inc. grew its position in Hologic by 3.6% during the third quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider’s stock valued at $21,957,000 after buying an additional 9,419 shares during the period. Diversified Trust Co purchased a new stake in Hologic during the fourth quarter worth about $506,000. Finally, Fulton Bank N.A. purchased a new position in Hologic in the fourth quarter valued at about $287,000. Institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now owns 5,445 shares of the company’s stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.88% of the stock is owned by insiders.

Hologic Stock Performance

Shares of HOLX opened at $56.74 on Friday. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $12.73 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The stock has a 50-day moving average price of $59.43 and a 200-day moving average price of $68.25.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.03 EPS. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on HOLX. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a report on Friday, May 2nd. Raymond James reiterated an “outperform” rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Evercore ISI dropped their price objective on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating on the stock in a report on Friday, May 2nd. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, Citigroup reduced their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and an average target price of $78.58.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.